{"schema_version":"1.0","type":"article","title":"GSK 砸 20 億美元買止咳新藥，三期卻翻車！","url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.md","lang":"zh-Hant","date":"2026-08-15","publish_at":"2026-08-15T09:30:00+08:00","updated_at":"2026-08-15","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","GSK","camlipixant","P2X3","慢性咳嗽","CALM-1","CALM-2","臨床三期","新藥研發","生技併購"],"summary":"GSK 約 20 億美元收購 BELLUS Health 後，camlipixant 的 CALM-1 達標、CALM-2 卻未能複製。這場第三期落差揭示：二期訊號、患者感受與可重現性必須一起過關。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖1｜同一個藥、同一劑量，CALM-1 與 CALM-2 得到不同的第三期結果","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-01.png"},{"alt":"圖2｜SOOTHE 二期訊號與約 20 億美元收購：買進的是後期假設，不是確定核准","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-02.png"},{"alt":"圖3｜第三期不是放大二期，而是用更大族群、更長追蹤重新檢驗結果能否重現","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-03.png"},{"alt":"圖4｜RCC 開發停止，BALANCE 第二期仍繼續：不同適應症不能直接外推","url":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/cover-v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-15）。GSK 砸 20 億美元買止咳新藥，三期卻翻車！。https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}